Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$6.70 USD
-0.02 (-0.30%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $6.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADVM 6.70 -0.02(-0.30%)
Will ADVM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADVM
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
Other News for ADVM
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Truist Financial Keeps Their Buy Rating on Adverum Biotechnologies (ADVM)
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD
Around $88M Bet On NextDecade? Check Out These 3 Stocks Insiders Are Buying
Adverum Biotechnologies announces FDA RMAT designation for Ixo-vec